SCHEMBL509560

SCHEMBL509560

CCN(CC)C(=O)c1cc(OC)c(OC)cc1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.54
HSP90AA1 P07900 1/20 0.54
HSP90AB1 P08238 1/20 0.54
BLM P54132 1/20 0.54
KDM4E B2RXH2 3/20 0.54
ALDH1A1 P00352 4/20 0.52
HPGD P15428 3/20 0.45
HMGCR P04035 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
PDE4B Q07343 1/20 0.43
OPRM1 P35372 1/20 0.43
OPRD1 P41143 1/20 0.43
PAX8 Q06710 1/20 0.43
NPC1 O15118 1/20 0.42
ALOX15 P16050 1/20 0.42
RAB9A P51151 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14064552 0.81 KDM4E (0.49) CYP1A2HSP90AA1HSP90AB1BLMKDM4E
SCHEMBL2336464 0.81 LCK (0.59) CYP1A2HSP90AA1HSP90AB1BLMKDM4E
SCHEMBL19015279 0.81 KDM4E (0.55) CYP1A2HSP90AA1HSP90AB1BLMKDM4E
SCHEMBL20147158 0.80 CYP3A4 (0.44) CYP1A2KDM4EALDH1A1HPGDHMGCR
SCHEMBL3739313 0.80 HPGD (0.51) CYP1A2HSP90AA1HSP90AB1BLMALDH1A1
SCHEMBL7287220 0.79 KDM4E (0.50) CYP1A2HSP90AA1HSP90AB1BLMKDM4E
SCHEMBL13696479 0.78 KDM4E (0.46) CYP1A2HSP90AA1HSP90AB1BLMKDM4E
SCHEMBL1536288 0.77 HTT (0.55) CYP1A2HSP90AA1HSP90AB1BLMKDM4E
SCHEMBL17689061 0.77 HSP90AA1 (0.72) CYP1A2HSP90AA1HSP90AB1BLMALDH1A1
SCHEMBL9171117 0.77 MEN1 (0.52) CYP1A2HSP90AA1HSP90AB1BLMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532020-B 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives REXAHN PHARMACEUTICALS INC 2015-02-25 CN disclosed
US-8933096-B2 Antimicrobial agents Rugers, The State University of New Jersey (US) 2015-01-13 US disclosed
US-20130116278-A1 ANTIMICROBIAL AGENTS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2013-05-09 US disclosed
US-8314123-B2 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof REXAHN PHARMACEUTICALS, INC. (US) 2012-11-20 US disclosed
EP-2423196-A1 5, 6 or 7-substituted-3-phenylisoquinolinamine derivatives and therapeutic use thereof Rexahn Pharmaceuticals, Inc. (US) 2012-02-29 EP disclosed
US-20120029012-A1 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF REXAHN PHARMACEUTICALS, INC. (US) 2012-02-02 US disclosed
WO-2011159926-A1 ANTIMICROBIAL AGENTS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2011-12-22 WO disclosed
US-8034829-B2 e.g. 3-(3-methoxyphenyl)isoquinolin-1-amine; antiproliferative and antigrowth agent; breast tumors, prostate tumors, colon tumors, ovary tumors, kidney tumors, pancreas tumors, glioblastoma and melanoma. REXAHN PHARMACEUTICALS, INC. (US) 2011-10-11 US disclosed
CN-101573337-A 5, 6 or 7-substituted-3- (hetero) aryl-isoquinolinamine derivatives as antitumor agents REXAHN PHARMACEUTICALS INC (US) 2009-11-04 CN disclosed
EP-2099765-A2 5, 6, OR 7-SUBSTITUTED-3-(HETERO)ARYLISOQUINOLINAMINE DERIVATIVES AS ANTITUMOR AGENTS Rexahn Pharmaceuticals, Inc. (US) 2009-09-16 EP disclosed
US-20080182871-A1 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof REXAHN PHARMACEUTICALS, INC. (US) 2008-07-31 US disclosed
WO-2008063548-A2 5, 6, OR 7-SUBSTITUTED-S- (HETERO)ARYLISOQUINOLINAMINE DERIVATIVES AS ANTITUMOR AGENTS REXAHN PHARMACEUTICALS, INC. (US) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116278-A1 ANTIMICROBIAL AGENTS MRPL21, ARG1, RPP30 CYP1A2 2201/4885HSP90AA1 1993/4885HSP90AB1 1828/4885
US-20080182871-A1 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof FANCD2, NRAS, CCND2 CYP1A2 203/4885HSP90AA1 3160/4885HSP90AB1 2624/4885
US-20120029012-A1 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF FANCD2, NRAS, CCND2 CYP1A2 203/4885HSP90AA1 3160/4885HSP90AB1 2624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.